This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letter  • Similar articles in this journal  Topic Collections  • Vascular Surgery  • Prognosis/ Outcomes  • Cardiovascular System, Other  • Alert me on articles by topic

Carlos H. Timaran, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In reply

We appreciate Dr Buskens' discerning comments and questions. Although our study was indeed an observational registry-based study, it is likely the largest cohort of its kind and represents the early outcomes of the vast majority of EVARs performed in the United States over the last 5 years.¹ Most other studies compare smaller populations, are restricted to major academic centers, and have highly selected patients and operators.^2-5 Our findings, however, confirm those of other large observational studies, which have clearly established that the high 30-day and in-hospital mortality reported in the EVAR trial 2 is not seen in the United States, even in the highest-risk patients or those unfit for open repair.^2-3 Although no randomized trial, except for EVAR 2, has assessed the perioperative outcomes of EVAR among the highest-risk patients, the immediate need of data that could justify its use warranted additional investigation in . . . [Full Text of this Article]

AUTHOR INFORMATION

RELATED ARTICLE

Endovascular Aortic Aneurysm Repair in Patients With the Highest Risk and In-Hospital Mortality in the United States
Carlos H. Timaran, Frank J. Veith, Eric B. Rosero, J. Gregory Modrall, Frank R. Arko, G. Patrick Clagett, and R. James Valentine
Arch Surg. 2007;142(6):520-525.
ABSTRACT | FULL TEXT  

RELATED LETTER

Denying May Yet Make Sense
Erik Buskens
Arch Surg. 2008;143(2):209.
EXTRACT | FULL TEXT